INM vs PATH · rev $4.9M vs P/E 19, rev $1.61B
InMed Pharmaceuticals Inc (INM) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
InMed Pharmaceuticals Inc (INM) is a drug manufacturers - specialty & generic company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported INM revenue for 2025-06-30 was $4.9M. Net income was -$8.2M. Revenue was up 7.5% from 2024-06-30 to 2025-06-30. INM currently screens at market cap $5.2M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
INM currently screens at market cap $5.2M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the INM and PATH stock pages for the full models.
Not investment advice.